Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trialsTina Baker, Hoda Sharifian, Paul J Newcombe, Patrick G Gavin, Mark N Lazarus, Madhu Ramaswamy, Wendy I White, Nicola Ferrari, Daniel Muthas, Raj Tummala, Eric F Morand, Richard A Furie, Edward M Vital, Chris Chamberlain, Adam PlattSee the full list of authors
3 April 2024
Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupusErica Moore, Sushma Bharrhan, Deepak A Rao, Fernando Macian, Chaim Putterman
26 March 2024
Disease activity drives divergent epigenetic and transcriptomic reprogramming of monocyte subpopulations in systemic lupus erythematosusAnna Guiomar Ferreté-Bonastre, Mónica Martínez-Gallo, Octavio Morante-Palacios, Celia Lourdes Calvillo, Josep Calafell-Segura, Javier Rodríguez-Ubreva, Manel Esteller, Josefina Cortés-Hernández, Esteban Ballestar
27 February 2024
KLF2 enhancer variant rs4808485 increases lupus risk by modulating inflammasome machinery and cellular homoeostasisManish Kumar Singh, Harikrishna Reddy Rallabandi, Xu-Jie Zhou, Yuan-Yuan Qi, Zhan-Zheng Zhao, Ting Gan, Hong Zhang, Loren L Looger, Swapan K Nath
19 February 2024
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohortIoannis Parodis, Julius Lindblom, Guillermo Barturen, Rafaela Ortega-Castro, Ricard Cervera, Jacques-Olivier Pers, Fernanda Genre, Falk Hiepe, Maria Gerosa, László Kovács, Ellen De Langhe, Silvia Piantoni, Georg Stummvoll, Carlos Vasconcelos, Barbara VigoneSee the full list of authors
19 February 2024
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progressionSofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George Bertsias
17 January 2024
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trialDi Wu, Jing Li, Dong Xu, Joan T Merrill, Ronald F van Vollenhoven, Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li, Jianhong Zhao, Dongbao Zhao, Cibo HuangSee the full list of authors
21 December 2023
Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosusYaoyang Liu, Zhiguo Zhang, Zijian Kang, Xu-jie Zhou, Shujun Liu, Shicheng Guo, Qianmei Jin, Ting Li, Ling Zhou, Xin Wu, Yan-na Wang, Liangjing Lu, Yanran He, Fubin Li, Hong ZhangSee the full list of authors
11 August 2023
Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flaresDoua F Azzouz, Ze Chen, Peter M Izmirly, Lea Ann Chen, Zhi Li, Chongda Zhang, David Mieles, Kate Trujillo, Adriana Heguy, Alejandro Pironti, Greg G Putzel, Dominik Schwudke, David Fenyo, Jill P Buyon, Alexander V AlekseyenkoSee the full list of authors
26 June 2023
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagyXin-yu Zhao, Shuang-shuang Li, Ying-xin He, Li-jie Yan, Fu Lv, Qi-meng Liang, Yu-hui Gan, Li-pei Han, Hong-de Xu, Yong-chun Li, Yuan-yuan Qi
24 July 2023
